Low ceiling respiratory depression by ciramadol.

Area of Science:

• Pharmacology
• Anesthesiology
• Respiratory Physiology

Background:

• Opioid analgesics are essential for pain management but can cause respiratory depression.
• Agonist-antagonist analgesics offer an alternative with potentially different safety profiles.
• Understanding the respiratory effects of novel analgesics like ciramadol is crucial for clinical application.

Purpose of the Study:

• To compare the respiratory depressant effects of ciramadol, a novel agonist-antagonist analgesic, with morphine, a pure agonist.
• To investigate the dose-response relationship of ciramadol on respiratory function.

Main Methods:

• Healthy volunteers received intravenous administration of ciramadol or morphine.
• Respiratory depression was quantified by measuring the displacement of the carbon dioxide response curve.
• Dose-escalation studies were performed for both agents.

Main Results:

• Ciramadol (30 mg/70 kg) produced respiratory depression comparable to morphine (10 mg/70 kg).
• Increasing doses of ciramadol up to 90 mg/70 kg did not result in further respiratory depression, indicating a ceiling effect.
• The maximal respiratory depression observed with ciramadol was approximately half that seen with nalbuphine and dezocine.

Conclusions:

• Ciramadol exhibits a ceiling effect on respiratory depression, distinguishing it from pure agonists like morphine.
• This ceiling effect may be a characteristic feature of agonist-antagonist analgesics.
• Ciramadol may offer a potentially safer respiratory profile compared to pure opioid agonists at higher doses.